HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Anesthesia · Medical Devices Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Anesthesia · Medical Devices Therapeutic Area Assessment

25 signals · 7 insights · 94 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 62%

Evidence

126 items

Sources

2

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Anesthesia · Medical Devices integrates 25 signals, 7 executive insights, and 94 regulatory precedents from the Humanexa intelligence graph. 1 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 21, 2026

    Baxter Faces Early Alert Over Intravascular Administration Set Air Bubble Issue

    Baxter's intravascular administration sets may contain air bubbles, posing a risk of air delivery to patients.

    View detail
  2. signalJul 17, 2026

    B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues

    Braun Medical is recalling convenience kits that contain Bupivacaine Hydrochloride in Dextrose Injection due to safety concerns.

    View detail
  3. signalJun 20, 2026

    Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk

    Draeger, Inc. is correcting additional anesthesia workstations due to a manufacturing error that may lead to ventilator failure.

    View detail
  4. signalJul 23, 2026

    Zydus Pharms receives AP status for Dexmedetomidine Hydrochloride ANDA206798

    Zydus Pharms has received an Abbreviated New Drug Application (ANDA) approval status for Dexmedetomidine Hydrochloride.

    View detail
  5. regulatoryJul 21, 2026

    Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Baxter.

    View detail
  6. regulatoryJul 21, 2026

    Early Alert: Convenience Kit Issue from Windstone Medical Packaging, Inc.

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Baxter.

    View detail
  7. regulatoryJul 21, 2026

    Positive Pressure Breathing Device Correction: Baxter Issues Correction for Volera Positive Pressure Breathing Devices

    Volara system patient circuits may leak air and medication from the nebulizer cup during therapy, leading to reduced oxygenation and ineffective nebulization.

    View detail
  8. regulatoryJul 21, 2026

    Early Alert: Positive Pressure Breathing Device Issue from Baxter

    Volara system patient circuits may leak air and medication from the nebulizer cup during therapy, leading to reduced oxygenation and ineffective nebulization.

    View detail
  9. insightJul 21, 2026

    Baxter's Intravascular Device Safety Alert: Regulatory and Competitive Implications

    The early alert regarding Baxter's intravascular administration sets poses significant safety concerns that could lead to regulatory scrutiny and potential recalls. This situation not only threatens patient safety but also Baxter's market position, creating opportunities for competitors to capitalize on any reputational damage. Regulatory context from FDA (Early Alert: Intravascular Administration Set Issue from Baxter) supports the near-term read. Assessment grounded in 18 ranked evidence items (8 high-relevance).

    View detail
  10. insightJul 17, 2026

    B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    The recall of B. Braun's spinal anesthesia kits due to safety concerns poses significant risks to the company's market position and reputation. This situation necessitates a thorough investigation to understand the implications for product safety and regulatory compliance. Regulatory context from FDA (FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

    View detail
  11. insightJul 1, 2026

    Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

    View detail
  12. insightJun 23, 2026

    FDA Approval of Succinylcholine Chloride: New Competitive Dynamics in Neuromuscular Blockers

    The FDA's approval of STERISCIENCE's generic Succinylcholine Chloride introduces a new competitor in the neuromuscular blocker market. This could lead to increased price competition and impact market share for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 5 ranked evidence items (3 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 7 risk-calibrated assessments for portfolio review. 94 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 1 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs

    72%

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Baxter.

    Source: FDA

    View evidence

  • Early Alert: Convenience Kit Issue from Windstone Medical Packaging, Inc.

    72%

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Baxter.

    Source: FDA

    View evidence

  • Positive Pressure Breathing Device Correction: Baxter Issues Correction for Volera Positive Pressure Breathing Devices

    72%

    Volara system patient circuits may leak air and medication from the nebulizer cup during therapy, leading to reduced oxygenation and ineffective nebulization.

    Source: FDA

    View evidence

  • Early Alert: Positive Pressure Breathing Device Issue from Baxter

    72%

    Volara system patient circuits may leak air and medication from the nebulizer cup during therapy, leading to reduced oxygenation and ineffective nebulization.

    Source: FDA

    View evidence

  • Early Alert: Intravascular Administration Set Issue from Baxter

    72%

    Baxter administration sets may have air bubbles in the drip chamber and tubing, which may result in air being delivered through the IV line to the patient.

    Source: FDA

    View evidence

  • FDA AP — ARGATROBAN (SUPPL)

    66%

    Application NDA201811. Sponsor: FRESENIUS KABI USA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ARGATROBAN.

    Source: FDA

    View evidence

  • Baxter's Intravascular Device Safety Alert: Regulatory and Competitive Implications

    66%

    The early alert regarding Baxter's intravascular administration sets poses significant safety concerns that could lead to regulatory scrutiny and potential recalls. This situation not only threatens patient safety but also Baxter's market position, creating opportunities for competitors to capitalize on any reputational damage. Regulatory context from FDA (Early Alert: Intravascular Administration Set Issue from Baxter) supports the near-term read. Assessment grounded in 18 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    57%

    The recall of B. Braun's spinal anesthesia kits due to safety concerns poses significant risks to the company's market position and reputation. This situation necessitates a thorough investigation to understand the implications for product safety and regulatory compliance. Regulatory context from FDA (FDA AP — BUPIVACAINE HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    69%

    The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Lidocaine Hydrochloride by Hospira is significant as it may strengthen Hospira's competitive position in the local anesthetic market. Companies with similar products should reassess their strategies in light of this development. Regulatory context from FDA (FDA AP — LIDOCAINE HYDROCHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 16 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

  • FDA Approval of Succinylcholine Chloride: New Competitive Dynamics in Neuromuscular Blockers

    68%

    The FDA's approval of STERISCIENCE's generic Succinylcholine Chloride introduces a new competitor in the neuromuscular blocker market. This could lead to increased price competition and impact market share for existing products in this therapeutic area. Regulatory context from FDA (FDA AP — SUCCINYLCHOLINE CHLORIDE (SUPPL)) supports the near-term read. Assessment grounded in 5 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Medline's Bupivacaine Recall: Strategic Risks and Opportunities in Anesthesia Market

    56%

    The recall of Medline's convenience kits containing Huons Bupivacaine Hydrochloride raises safety concerns that could undermine customer trust and impact market share in the anesthesia segment. Portfolio teams need to evaluate the potential revenue implications and develop strategies to address customer concerns and mitigate losses. Regulatory context from FDA (Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP) supports the near-term read. Assessment grounded in 22 ranked evidence items (5 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Trends in Anesthesia: Ketamine, Bupivacaine, and Opioid-Free Strategies

    63%

    This study could significantly influence anaesthesia practices by validating ketamine's role as an adjunct therapy, potentially altering the competitive landscape for anaesthetic agents. A successful outcome may lead to revised clinical guidelines and increased adoption of ketamine in anaesthesia protocols. Assessment grounded in 17 ranked evidence items (8 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Baxter Faces Early Alert Over Intravascular Administration Set Air Bubble Issue

    Safety Signal

  • B. Braun Medical Recalls Spinal Anesthesia Kits Due to Bupivacaine Hydrochloride Issues

    Safety Signal

  • Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk

    Safety Signal

  • Zydus Pharms receives AP status for Dexmedetomidine Hydrochloride ANDA206798

    Regulatory Approval

  • FDA Accepts Supplement Application for Rocuronium Bromide by Fresenius Kabi

    Regulatory Approval

  • FDA Grants Approval for Propofol ANDA220857 by Anthea Pharma

    Regulatory Approval

  • FDA Submission Update for Sugammadex by Tamarang SA

    Regulatory Approval

  • Trial on Low-Dose Remimazolam for Emergence Agitation in Oral Surgery

    Trial Update

Insights

  • Baxter's Intravascular Device Safety Alert: Regulatory and Competitive Implications

    Medical Devices · IV Administration

  • B. Braun's Recall of Bupivacaine Hydrochloride Kits Signals Regulatory and Competitive Risks

    Anesthesia · Injectable

  • Hospira's Lidocaine Hydrochloride Approval Enhances Competitive Position in Anesthesia

    Anesthesia · Local Anesthetic

  • FDA Approval of Succinylcholine Chloride: New Competitive Dynamics in Neuromuscular Blockers

    Anesthesia · Neuromuscular Blocker

  • Medline's Bupivacaine Recall: Strategic Risks and Opportunities in Anesthesia Market

    Anesthesia · Local Anesthetics

  • Emerging Trends in Anesthesia: Ketamine, Bupivacaine, and Opioid-Free Strategies

    Anesthesia · Ketamine

  • Draeger Faces Competitive Pressure Amid Anesthesia Machine Safety Concerns

    Anesthesia · Medical Devices

Companies

  • Anthea Pharma

    2 signals

Assets

  • Hospira
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.